SRNE News and Press, Sorrento Therapeutics Inc. From 07/27/21

Sorrento Therapeutics is ready to market the COVI-STIX in Mexico with 25 million test units. The company is planning to file a Biologics License Application for the Infliximab biobetter in the US and the EU. Short interest at 52-week low. For further details see: Sorrent...

China Oncology Focus has enrolled the first patient in China in the late-stage trial of socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer ((ES-SCLC)). China Oncology had received exclusive rights to develop and commerci...

China Oncology Focus, a subsidiary of Lee’s Pharm, has enrolled the first patient in the Socazolimab double-blinded Phase 3 study in combination with chemotherapy as a first-line treatment of extensive-stage small-cell lung cancer. Socazolimab is an anti-PD-L1 antibody licensed...

Palm Beach, FL – July 22, 2021 – According to WebMD, this week the nation’s top health officials said Tuesday that the Delta variant of the coronavirus is racing through North America and other parts of the world and now is responsible for 83% of all U...

Anti-TROP-2 coupled to SN38 (a DNA polymerase inhibitor) (ESG-401) has received approval to begin clinical trials. ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma. SAN DIEGO, Jul...

Sorrento Therapeutics (SRNE) announces that COVID-19 patients have been dosed in the company's Phase 2 efficacy trial of COVIDROPS.About 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms will be enrolled in the large double-blind, randomized trial evaluating C...

COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in this large Phase 2 efficacy trial in the United Kingdom. COVIDROPS™ neutralizing antibody is administered by intranasal instillation. COVIDROPS is highly active against the original SARS-Co...

Sorrento Therapeutics ([[SRNE]] +2.6%) announces the formation a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico.The subsidiary is meant to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and com...

Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico. Sorrento’s Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units....

Sorrento Therapeutics ([[SRNE]] -1.2%) company Scilex Holding has completed enrollment in late-stage trial of SP-102 for the treatment of lumbosacral radicular pain ((sciatica)).The trial has randomized 400 patients at 40 sites across 25 states in the U.S. with the pr...